Liyun Yuan, MD, PhD

Dr. Yuan is a transplant hepatologist specializing in caring for patients with chronic liver diseases, hepatocellular carcinoma, and pre-/post liver transplantation. She completed her internship and residency training in Internal Medicine at Keck USC School of Medicine, where she further finished gastroenterology fellowship training. After that, she took an extra year advanced training in transplant hepatology at University of Colorado, Denver.

Dr. Yuan’s clinical research interests include Nonalcoholic fatty liver disease, autoimmune hepatitis and outcome of liver transplantation. She has authored several articles in peer-reviewed journals on various topics in liver disease and liver transplantation. Dr. Yuan’s research activities include searching and validating diagnostic markers and prognostic makers in nonalcoholic steatohepatitis, liver targeting of anti-fibrotic therapy, and the role of PGAM5 in hepatic cell death- using the model of acetoaminophen-induced liver injury.

• American Association of Pharmaceutical Sciences: Graduate Student Award, 2006
• Charles and Charlotte Krown Fellowship, 2005
• Rho Chi Pharmacy Honor Society: Member, 2004

• Hepatol Commun. 2022 11; 6(11):3003-3005. . View in PubMed
• Metabolic Risk Profiles for Hepatic Steatosis Differ by Race/Ethnicity: An Elastography-Based Study of US Adults Dig Dis Sci. 2022 07; 67(7):3340-3355. . View in PubMed
• Racial disparities in bariatric surgery postoperative weight loss and patient satisfaction Am J Surg. 2022 05; 223(5):969-974. . View in PubMed
• Nonalcoholic Fatty Liver Disease: The Role of Visceral Adipose Tissue Clin Liver Dis (Hoboken). 2022 Mar; 19(3):106-110. . View in PubMed
• Portrait of Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis in the United States Am J Gastroenterol. 2022 03 01; 117(3):433-444. . View in PubMed
• No Foul Play for Transjugular Intrahepatic Portosystemic Shunts in Liver Transplantation for Hepatocellular Carcinoma Liver Transpl. 2021 11; 27(11):1680-1681. . View in PubMed
• Applying the original model for end-stage liver disease score rather than the model for end-stage liver disease-Na score for risk stratification prior to transjugular intrahepatic portosystemic shunt procedures Eur J Gastroenterol Hepatol. 2021 04 01; 33(4):541-546. . View in PubMed
• IgG:IgM Ratios of Liver Plasma Cells Reveal Similar Phenotypes of Primary Biliary Cholangitis With and Without Features of Autoimmune Hepatitis Clin Gastroenterol Hepatol. 2021 02; 19(2):397-399. . View in PubMed
• PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver Hepatobiliary Surg Nutr. 2020 Jun; 9(3):353-356. . View in PubMed
• NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities Curr Hepatol Rep. 2019 Dec; 18(4):425-432. . View in PubMed
• Bile acid receptors and nonalcoholic fatty liver disease World J Hepatol. 2015 Dec 08; 7(28):2811-8. . View in PubMed
• Mechanisms of drug-induced liver injury Clin Liver Dis. 2013 Nov; 17(4):507-18vii. . View in PubMed
• Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria Trends Pharmacol Sci. 2013 Apr; 34(4):243-53. . View in PubMed
• Glutathione in liver diseases and hepatotoxicity Mol Aspects Med. 2009 Feb-Apr; 30(1-2):29-41. . View in PubMed
• Reversible lipidization of somatostatin analogues for the liver targeting Eur J Pharm Biopharm. 2008 Oct; 70(2):615-20. . View in PubMed
• Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs J Control Release. 2008 Jul 02; 129(1):11-7. . View in PubMed
• Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide Pharm Res. 2005 Feb; 22(2):220-7. . View in PubMed

• Kaplowitz, Neil
• Terrault, Norah
• Emamaullee, Juliet
• Zhou, Kali
• Gonzalez, Frank